Nymox Pharmaceutical Corporation is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also has a patent portfolio covering its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company has two subsidiaries: one wholly owned subsidiary Nymox Corporation and the other a majority owned subsidiary Serex, Inc. Nymox Corporation conducts research and development, while Serex conducts research and development and some of the manufacturing for NicAlert and TobacAlert.